Skip to main content
. 2017 Nov 8;15(1):1005–1012. doi: 10.3892/etm.2017.5470

Figure 3.

Figure 3.

Effects of MgIG treatment on the expression of (A and B) Bax, Bcl-2, (C and D) caspase-3 and (E and F) NF-κBp65 in liver and heart tissues, measured by western blot analysis. The calculated relative intensities of Bax/Bcl-2, caspase-3/β-actin, and NF-κBp65/β-actin are presented under the representative immunoblots for each group. Data are presented the mean ± standard error of the mean. *P<0.05 and **P<0.01 vs. the DOX group; ##P<0.01 vs. the control group. MgIG, magnesium isoglycyrrhizinate; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; NF-κBp65, nuclear factor κBp65; DOX, doxorubicin; L-MgIG, low-dose MgIG; M-MgIG, medium-dose MgIG; H-MgIG, high-dose MgIG.